• Purity

  >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its binding ability in a functional ELISA. When Recombinant Human FGF basic 146 aa Recombinant Human FGF basic 146 aa (Catalog # ) is coated at 1.5 µg/mL, 100 μL/well, Recombinant Human KAL1 binds with an ED    ₅₀ of 8-48 ng/mL.

• Source

  Chinese Hamster Ovary cell line, CHO-derived Ala25-Tyr680, with a C-terminal 6-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  Ala25

• Predicted Molecular Mass

  75 kDa

• SDS-PAGE

  84-103 kDa, reducing conditions

Data Images

Background: KAL1

Anosmin-1, also known as Kal-1, is a 100 kDa secreted glycoprotein that regulates neuronal adhesion and migration. Mutations in Anosmin-1 are associated with the development of X-linked Kallman syndrome which can be accompanied by hearing loss (1). Mature human Anosmin-1 contains one WAP domain and four Fibronectin type-III domains (2). It is expressed by cerebellar Purkinje cells and deep nuclear neurons (2, 3), piriform cortex and olfactory bulb mitral cells (2, 4), optic tectum and retinal ganglion axons (2, 5, 6), and oligodendrocyte progenitor cells (OPC) (4). Anosmin-1 binds to Integrin beta 1/CD29, FGF R1, L1CAM, and complexes of FGF R1 with FGF basic and heparan sulfate proteoglycans, and it enhances signaling through FGF R1 (6-9). It mediates OPC adhesion, inhibits FGF basic-induced OPC migration, and enhances oligodendrocyte-mediated axon myelination (5, 6, 10, 11). It also cooperates with FGF basic to promote olfactory axon elongation and neurite outgrowth (3, 4, 8, 9, 12, 13). In addition, Anosmin-1 is up-regulated in glioblastoma and gastric cancer where it enhances tumor cell proliferation and migration (7, 14).

• References:

1. Korsensky, L. and D. Ron (2016) Semin. Cell Dev. Biol. 53:101.

2. Soussi-Yanicostas, N. et al. (1996) J. Cell Sci. 109:1749.

3. Gianola, S. et al. (2009) Neuroscience 158:570.

4. Soussi-Yanicostas, N. et al. (2002) Cell 109:217.

5. Bribian, A. et al. (2008) Dev. Neurobiol. 68:1503.

6. Bribian, A. et al. (2006) Mol. Cell. Neurosci. 33:2.

7. Choy, C.T. et al. (2013) Endocr. Relat. Cancer 21:85.

8. Diaz-Balzac, C.A. et al. (2015) Cell Rep. 11:1377.

9. Gonzalez-Martinez, D. et al. (2004) J. Neurosci. 24:10384.

10. Clemente, D. et al. (2011) J. Neurosci. 31:14899.

11. Murcia-Belmonte, V. et al. (2016) Brain Struct. Funct. 221:1365.

12. Soussi-Yanicostas, N. et al. (1998) J. Cell Sci. 111:2953.

13. Garcia-Gonzalez, D. et al. (2016) Brain Struct. Funct. 221:239.

14. Kanda, M. et al. (2016) Int. J. Cancer 138:721.

• Long Name:

  Kallmann Syndrome 1 Sequence

• Entrez Gene IDs:

  3730 (Human)

• Alternate Names:

  ADMLX; ANOS1; Anosmin 1; CDK5 regulatory subunit associated protein 1-like 1; CDK5 regulatory subunit-associated protein 1-like 1; FLJ20342; FLJ46705; HH1; HHA; KAL; KAL1; KALIG-1; KMS; MGC75469